English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Company Presentation
ESG Reports
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
Announcements & Circulars
The announcement begins in December 2019
GRANT OF SHARE OPTIONS
2021-04-23
VOLUNTARY ANNOUNCEMENT - PRELIMINARY SAFETY TOLERABILITY AND EFFICACY RESULTS OF KN046 IN COMBINATION WITH NAB-PACLITAXEL IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER RELEASED FOR E-POSTER PRESENTATION AT 2021 AACR ANNUAL MEETING
2021-04-12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2021
2021-04-09
VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF MEDICAL OFFICER AND CHIEF FINANCIAL OFFICER
2021-03-30
ADOPTION OF THE RESTRICTED SHARE AWARD SCHEME
2021-03-23
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020
2021-03-23
DATE OF BOARD MEETING
2021-03-11
VOLUNTARY ANNOUNCEMENT - IND APPROVAL RECEIVED FOR A PHASE II CLINICAL TRIAL OF KN046 IN THE U.S.
2021-03-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021
2021-03-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2021
2021-02-05
20
21
22
23
24
25
26
PREV
23/30
NEXT